中华内分泌代谢杂志
中華內分泌代謝雜誌
중화내분비대사잡지
CHINESE JOURNAL OF ENDOCRINOLOGY AND METABOLISM
2011年
4期
287-291
,共5页
郑丕媚%苏喆%马华梅%杜敏联%陈秋莉%李燕虹%陈红珊
鄭丕媚%囌喆%馬華梅%杜敏聯%陳鞦莉%李燕虹%陳紅珊
정비미%소철%마화매%두민련%진추리%리연홍%진홍산
促性腺激素释放激素类似物%生长激素%青春期,早熟%成年身高
促性腺激素釋放激素類似物%生長激素%青春期,早熟%成年身高
촉성선격소석방격소유사물%생장격소%청춘기,조숙%성년신고
Gonadotropin-releasing hormone analogue%Growth hornmne%puberty,precocious%Adult height
目的 观察重组人生长激素(rhGH)对于促性腺激素释放激素类似物(GnRHa)治疗中生长过度减速的特发性中枢性性早熟(ICPP)女孩的最终成年身高(FAH)的影响.方法 49例ICPP女孩接受GnRHa治疗,当身高增长速度减慢至4 cm/年以下时,其中26例联用rhGH治疗为联合治疗组,23例拒绝加用rhGH但继续使用GnRHa为单用组.比较2组治疗前后的预测成年身高(PAH)和FAH.结果 联合治疗组联用rhGH前半年,身高增长速度均小于4 cm/年[(3.2±1.0)cm/年],PAH无明显改善[联用rhGH前半年和rhGH开始时PAH分别为(152.5±4.0)cm和(152.6±3.7)cm];联用rhGH(11.4±5.4)个月后,身高增长速度增加至(6.7±2.0)cm/年,PAH增加至治疗结束时的(157.1±4.7)cm(均P<0.01);FAH[(157.5±4.5)cm]显著高于GnRHa开始时的PAH[(148.1±4.6)cm]和遗传靶身高[(154.4±4.6)cm,均P<0.01].单用组治疗结束时的PAH[(153.9±6.3)cm]较拒绝联用rhGH时的PAH[(153.1±6.2)cm]无差异;FAH[(154.7±5.5)cm]高于治疗开始时的PAH[(150.3±6.0)cm,P<0.01],但与遗传靶身高[(155.6±4.3)cm]无差异.结论 联用rhGH能够显著加快GnRHa治疗中生长过度减速的ICPP女孩的身高增长速度,进一步改善PAH和FAH.
目的 觀察重組人生長激素(rhGH)對于促性腺激素釋放激素類似物(GnRHa)治療中生長過度減速的特髮性中樞性性早熟(ICPP)女孩的最終成年身高(FAH)的影響.方法 49例ICPP女孩接受GnRHa治療,噹身高增長速度減慢至4 cm/年以下時,其中26例聯用rhGH治療為聯閤治療組,23例拒絕加用rhGH但繼續使用GnRHa為單用組.比較2組治療前後的預測成年身高(PAH)和FAH.結果 聯閤治療組聯用rhGH前半年,身高增長速度均小于4 cm/年[(3.2±1.0)cm/年],PAH無明顯改善[聯用rhGH前半年和rhGH開始時PAH分彆為(152.5±4.0)cm和(152.6±3.7)cm];聯用rhGH(11.4±5.4)箇月後,身高增長速度增加至(6.7±2.0)cm/年,PAH增加至治療結束時的(157.1±4.7)cm(均P<0.01);FAH[(157.5±4.5)cm]顯著高于GnRHa開始時的PAH[(148.1±4.6)cm]和遺傳靶身高[(154.4±4.6)cm,均P<0.01].單用組治療結束時的PAH[(153.9±6.3)cm]較拒絕聯用rhGH時的PAH[(153.1±6.2)cm]無差異;FAH[(154.7±5.5)cm]高于治療開始時的PAH[(150.3±6.0)cm,P<0.01],但與遺傳靶身高[(155.6±4.3)cm]無差異.結論 聯用rhGH能夠顯著加快GnRHa治療中生長過度減速的ICPP女孩的身高增長速度,進一步改善PAH和FAH.
목적 관찰중조인생장격소(rhGH)대우촉성선격소석방격소유사물(GnRHa)치료중생장과도감속적특발성중추성성조숙(ICPP)녀해적최종성년신고(FAH)적영향.방법 49례ICPP녀해접수GnRHa치료,당신고증장속도감만지4 cm/년이하시,기중26례련용rhGH치료위연합치료조,23례거절가용rhGH단계속사용GnRHa위단용조.비교2조치료전후적예측성년신고(PAH)화FAH.결과 연합치료조련용rhGH전반년,신고증장속도균소우4 cm/년[(3.2±1.0)cm/년],PAH무명현개선[련용rhGH전반년화rhGH개시시PAH분별위(152.5±4.0)cm화(152.6±3.7)cm];련용rhGH(11.4±5.4)개월후,신고증장속도증가지(6.7±2.0)cm/년,PAH증가지치료결속시적(157.1±4.7)cm(균P<0.01);FAH[(157.5±4.5)cm]현저고우GnRHa개시시적PAH[(148.1±4.6)cm]화유전파신고[(154.4±4.6)cm,균P<0.01].단용조치료결속시적PAH[(153.9±6.3)cm]교거절련용rhGH시적PAH[(153.1±6.2)cm]무차이;FAH[(154.7±5.5)cm]고우치료개시시적PAH[(150.3±6.0)cm,P<0.01],단여유전파신고[(155.6±4.3)cm]무차이.결론 련용rhGH능구현저가쾌GnRHa치료중생장과도감속적ICPP녀해적신고증장속도,진일보개선PAH화FAH.
Objective To evaluate the long-term final adult height outcome of combined treatment with gonadotropin-releasing hormone analogue(GnRHa)and recombinant human growth hormone(rhGH)in girls with idiopathic central precocious puberty(ICPP).Methods Out of 49 sirls with ICPP[treated with GnRHa at a dose of 60-80 μg/kg every 4 weeks for at least 6 months,whose height velocity fell below 4 cm/year and showed no improvement of predicted adult height(PAH)in 6 months],26 received(rhGH-combined group),in addition to chronological age,and duration of GnRHa treatment,who showed the same growth pattern but refused rhGH treatment,served to evaluate the efficacy of rhGH in addition.At the conclusion of the smdy,all the girls had been followed up for(3.3±1.9)years,and(3.2±0.9)years in rhGH-combined group and control group,respectively;and had achieved adult heisht.To compare the PAH with the final adult height(FAH)before and after treatment in the two groups.Results During rhGH treatment, height velocity of the rhGH-combined girls increased significantly[(6.7±2.0 vs <4)cm/year baseline],RhGH-combined gids showed an adult height far higher than pretreatment PAH [(157.5±4.5 vs 148.1±4.6)cm,P<0.01],and target height[(154.4±4.6)cm] was,significantly excceded.The control group reached an adult heisht also significandy higher than pretreatment PAH[(154.7±5.5vs 150.3±6.0)cm,P<0.01],while target height[(155.6±4.3)cm]was just reached but not significantlyexcceded.The gain in height obtained,calculated between pretreatment PAH and final heisat,(9.4±4.9)cm in rhGH-combined group was much more than that(4.3±4.2)cm in the control group(P<0.01).Conclusion RhGH may accelerate the linear growth and improve adult height of GnRHa-treated ICPP girls.
